Rockefeller Capital Management
SKYE icon

Rockefeller Capital Management’s Skye Bioscience SKYE Stock Holding History

Rockefeller Capital Management’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27 Hold
5
– – ﹤0.01% 4705
2026
Q1 		$24 Hold
5
– – ﹤0.01% 4660
2025
Q4 		$29 Hold
5
– – ﹤0.01% 4651
2025
Q3 		$153 Buy
+5
New +$151 ﹤0.01% 4358

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rockefeller Capital Management's SKYE Position: Q2 2026 in Review

Rockefeller Capital Management held its Skye Bioscience (SKYE) position steady in Q2 2026 at 5 shares worth $27. The position accounts for ﹤0.01% of the portfolio, ranked #4705.

Rockefeller Capital Management first reported a position in SKYE in Q3 2025 and has held it in 4 quarters since. The position peaked at $153 in Q3 2025. 33 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Rockefeller Capital Management held 5 shares of Skye Bioscience worth $27 as of Q2 2026.
  • Rockefeller Capital Management left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4705 holding.
  • Rockefeller Capital Management first reported a position in Skye Bioscience in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Skye Bioscience position peaked at $153 in Q3 2025.
  • 33 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.